Special topicPlaytoearncryptoappTransaction Tip
Stock speculation to see Jin Kirin analyst research report, authoritative, professional, timely, comprehensive, to help you tap the potential of the theme opportunity!
[hot spots]
Zhengzhou Coal Power: there is still a gap between the relevant coal assets of Zhengzhou Coal Group and the conditions for injection into listed companies.
Zhengzhou Coal Power (600121) issued a clarification announcement on the evening of May 24, 2024, when investors asked, "when will the company's controlling shareholders promise to inject high-quality coal assets into listed companies in 2018?" Yu Zeyang, chairman and vice chairman of Zheng Coal Group, answered the question, saying that Zheng Coal Group has been committed to the overall listing of the main coal industry for many years, but at present, the relevant coal assets of Zheng Coal Group have not yet met the requirements of asset securitization, and there is still a gap between the conditions for injection into listed companies.
King Kong Photovoltaic: no significant changes have taken place in the current business situation and internal and external business environment.
King Kong Photovoltaic (300093) disclosed changes in stock trading notice on the evening of May 24, 2024, according to the company's inquiry, the relevant media reported that the China Photovoltaic Industry Association recently organized a "Symposium on High-quality Development of the Photovoltaic Industry" in Beijing. After the opening of the day, affected by this news, photovoltaic stocks rose generally, which had a greater impact on the company's stock trading price fluctuations. No significant changes have taken place in the company's current operating situation and internal and external operating environment. The company, the controlling shareholder and the actual controller do not have significant matters that should be disclosed but not disclosed by the company or are in the planning stage.
Huafeng Technology: no major adjustment has taken place in the market environment and industry policy of the connector industry in which the company is located.
Huafeng Technology (688629) disclosed the stock trading change notice on the evening of May 24th, saying that after the company's self-examination, the company's daily operating conditions and external environment had not undergone significant changes. The market environment and industry policy of the connector industry where the company is located has not been significantly adjusted, and the internal business order is normal.
Digital Zhengtong: the company releases new products such as low-altitude economic SAAS platform.
Digital Zhengtong (300075) announced on the evening of May 24th that the company attended the Seventh Digital China Summit and successfully held the 2024 Digital China Partnership Conference on May 23rd. At the meeting, Digital Zhengtong officially released two innovative products, "Star Program-Building a city-level low-level economic SAAS platform for the integration of space and space," and "carbon sequestration Monitoring and Management Digital platform", and signed a strategic cooperation contract with 10 major cities and 30 + partners.
[M & A]
Nanjing Business Travel: planning to issue shares and pay cash for asset purchase stock trading suspension
Nanjing Business Travel (600250) announced on the evening of May 24th that the company is planning to buy 100% stake in Huangpu Hotel held by Tourism Group and 49% stake in Nanshang operation held by Nanjing Commercial Building and raise matching funds by issuing shares and paying cash. After the completion of this transaction, Huangpu Hotel and Nanshang will become wholly owned subsidiaries of the company. The company's shares will be suspended from trading on Monday, May 27, 2024, and are expected to be suspended for no more than 10 trading days.
[refinancing]
Tengjing Technology: it is proposed to raise no more than 4.Playtoearncryptoapp8500 million yuan
Tengjing Science and Technology (688195) announced on the evening of May 24th that it is proposed to raise no more than 485 million yuan for optoelectronics key and core components construction project (Phase III), Thailand production base construction project, R & D center construction project (Phase II).
[increase or decrease holdings, buybacks]
China Nuclear Titanium dioxide (rights protection): the vice chairman's plan to increase the company's shares has been completed.
China Nuclear Titanium dioxide (002145) announced on the evening of May 24th that as of the date of this announcement, Vice Chairman Shen Xin had accumulated 77.4206 million shares of the company, with an increase of 333 million yuan, accounting for 2% of the company's total share capital, which has reached the lower limit of this increase plan. the plan to increase holdings has been completed.
Liancheng Precision: 250000 shares of the company are increased by the controlling shareholder
Liancheng Precision (002921) announced on the evening of May 24th that Guo Yuanqiang, the company's controlling shareholder and real controller, increased his stake in the company by way of centralized bidding on May 23 and May 24, accounting for 0.191% of the company's total shares.
Product Golden Wheel: Jinlun Holdings intends to reduce its stake in the company by no more than 3%.
Property Golden Wheel (002722) announced on the evening of May 24th that Nantong Jinlun Holdings Co., Ltd. (referred to as "Golden Wheel Holdings"), which holds 13.51% of the company's shares, plans to reduce its holdings in no more than 6.1973 million shares (accounting for 3% of the company's total share capital) within 3 months after 15 trading days. Jinlun Holdings does not belong to the controlling shareholder and the actual controller of the company, and the implementation of this reduction plan will not lead to a change in the control of the company.
Sheng long shares: controlling shareholders and concerted actors intend to reduce their holdings of no more than 2.96% of the company's shares
Sheng long shares (603178) announced on the evening of May 24th that Shenglong Group, the company's controlling shareholder, and its concerted actor, Shengdar, intend to reduce their holdings of no more than 7 million shares in the company by means of centralized bidding and bulk trading, that is, no more than 2.96% of the total shares of the company.
Yawei shares: some directors propose to reduce their holdings of no more than 2.41% of the company's shares.
Yawei shares (002559) announced on the evening of May 24th that company directors Leng Zhibin, Shi Jinxia, Ji Suqin, Pan Enhai, Zhu Pengcheng and Fan Jun planned to reduce part of their holdings in the company by centralized bidding or block trading within 3 months after 15 trading days (June 18-September 17). The total number of shares to be reduced this time shall not exceed 13.245 million shares, that is, no more than 2.41% of the total share capital of the company.
Hausen Intelligence: two shareholders plan to reduce their shares in the company by no more than 2.39%.
Hausen Intelligence (688529) announced on the evening of May 24th that Shang Rong Innovation and Shang Rong Juyuan, the company's shareholders, intend to reduce their holdings in the company by centralized bidding or block trading, with a total of no more than 4 million shares, that is, no more than 2.3911% of the company's total share capital. Shang Rong Innovation Monk Rongyuan is a concerted actor, holding a total of 5 million shares of the company, accounting for 2.9889% of the company's total share capital.
An Biping: shareholders plan to reduce their shares of the company by no more than 2%
An Biping (688393) announced on the evening of May 24th that Nanjing Qianjing, a shareholder with a stake of 5.73%, intends to reduce its holding of no more than 1.8713 million shares (including capital) through block transactions, and no more than 2% of the company's current total share capital.
Huaheng Biology: shareholder Ma Anshan Cornerstone plans to reduce its stake in the company by no more than 2%.
Huaheng Biological (688639) announced on the evening of May 24th that Ma Anshan Cornerstone, which holds 2.38 per cent of its shares, plans to reduce its holdings by no more than 2 per cent of the company's total shares through centralized bidding and / or block trading.
Walter Gas: shareholders intend to reduce their shares in the company by no more than 2%.
Walter Gas (688268) announced on the evening of May 24th, shareholders Xiamen Huahong Duofu Investment Partnership (limited partnership), Xiamen Huajin Duofu Investment Partnership (limited partnership) and Xiamen Huajin Duofu Investment Partnership (limited partnership) directly hold 20.9% of the company's shares, and intend to reduce their holdings in the company by means of bulk transactions, not more than 2.4 million shares, accounting for no more than 2% of the company's total share capital.
Yang Guang Nuohe: shareholder Liu Yujing terminates the agreement transfer plan and intends to reduce 1.35% of the company's shares.
Yangguang Nuohe (688621) announced on the evening of May 24th that up to now, Liu Yujing, who holds 5.42% of the shares, disclosed on March 16, 2024, "Beijing Yangguang Nuohe Pharmaceutical Research Co., Ltd., a reminder of the plan to increase the number of shareholders holding more than 5% of the shares." the shareholders have not carried out the share transfer and have decided to terminate the transfer plan. In addition, Liu Yujing plans to reduce the company's shares through block transactions, totaling no more than 1.5168 million shares, or no more than 1.35 per cent of the company's total share capital.
Fangsheng Pharmaceutical: symbiotic Investment intends to reduce its stake in the company by no more than 1.21%
Fangsheng Pharmaceutical (603998) announced on the evening of May 24th that Taizhou Symbiosis Venture Capital Management Co., Ltd. (referred to as "symbiotic Investment"), which is 3.28% of the company's shares, intends to reduce its holdings of no more than 5.3031 million shares (1.21% of the company's total share capital).
Shanda latitude: shareholders intend to reduce their shares of the company by no more than 1%
Shanda Diwei (688579) announced on the evening of May 24th that shareholder Guoshou Chengda holds 5.15% of the company's shares and plans to reduce its total stake in the company to no more than 4.0001 million shares, that is, no more than 1% of the company's total share capital.
China UAV: shareholders intend to reduce their shares in the company by no more than 0.83%
China UAV (688297) announced on the evening of May 24th that the 8.24% shareholder, Chengdu Industrial Investment Co., Ltd. plans to reduce its stake in the company by centralized bidding to no more than 5.6219 million shares (that is, no more than 0.83% of the company's total share capital).
Jida Zhengyuan: some directors and supervisors intend to reduce their holdings of no more than 0.04% of the company's shares
Jida Zhengyuan (003029) announced on the evening of May 24 that some directors and supervisors of the company intend to reduce their holdings of some of the company's shares by centralized bidding within 3 months after 15 trading days. the total number of shares held by the relevant directors and supervisors is 336000 shares, accounting for 0.18% of the total share capital of the company excluding the repurchase special account, and the total number of shares to be reduced is not more than 84000 shares. It accounts for 0.04% of the total share capital of the company after excluding the repurchase special account.
[winning contract]
China Architecture: recently won a total of 26.01 billion yuan of major projects
China Construction (601668) announced on the evening of May 24th that recently, the company received a total of 26.01 billion yuan in major projects, accounting for 1.1% of the company's audited operating income in 2023.
Enlightening design: joint bid-winning project of 1.081 billion yuan
Enlightening Design (300500) announced on the evening of May 24th that the company recently formed a consortium with Jiangsu Yonglian Jingzhu Construction Group Co., Ltd., and participated in the invitation tender for the "Design, Procurement and Construction General contract (EPC)" of the "Su Land 2022 WG-3 Land Project" industrial park project. Today, the company received a "bid winning notice" from the tenderer, with the winning price of 1.081 billion yuan, accounting for 67.74% of the audited business income in 2023. According to the consortium agreement, the company, as the leader, is mainly responsible for the design and general contract management of the project, while the consortium members are mainly responsible for project procurement and construction.
Huadian heavy Industry: sign 967 million yuan PC general contract
Huadian heavy Industry (601226) announced on the evening of May 24th that the company and Huadian Xineng (Wenling) Photovoltaic Power Generation Co., Ltd. (hereinafter referred to as "Huadian Wenling") signed the "Zhejiang Huadian Wenling 200MW beach photovoltaic project PC general contract", the contract amount is about 967 million yuan (including tax).
Nenghui Science and Technology: sign 266 million yuan project general contract
Nenghui Technology (301046) announced on the evening of May 24th that the company disclosed the "notice of receipt of bid winning notice" on December 5, 2023. Recently, the company and China Power Construction Guizhou Institute, a subsidiary of China Electric Power Construction, signed a general contract (referred to as "contract" and "contract II") for the above-mentioned winning project, with a contract amount of 132 million yuan and 134 million yuan respectively.
Huakang Medical: won the bid 77.6874 million yuan laboratory construction project
Huakang Medical (301235) announced on the evening of May 24th that the company won the bid for the construction of the first section of Dalian Yingshi Science City Laboratory Technology Project (the first phase of the first opening area), the winning bid price was 77.6874 million yuan, accounting for 4.85% of the company's audited operating income in 2023.
[major investment]
Shaanxi natural gas: 3.787 billion yuan to be invested in the first phase of the Yulin-Xi'an gas pipeline project
Shaanxi Natural Gas (002267) announced on the evening of May 24th that in order to meet the market demand and enhance the transmission and distribution capacity of the pipe network, the company plans to invest in the construction of the first phase of the Yulin-Xi'an gas pipeline project (from Yichuan gas compression station to Xi'an Lintong sub-transmission station). The project starts at Yichuan compressor station and ends at Xi'an Lintong sub-transmission station, with a total length of about 277.66 km, pipe diameter DN1000, design pressure of 8.0 MPA, design annual gas transmission capacity of 11.6 billion square meters, a total of 5 stations and 11 valve chambers, with an investment of about 3.787 billion yuan.
Shenghong Technology: plans to build a production base in Vietnam with no more than 260 million US dollars
Shenghong Technology (300476) announced on the evening of May 24th that the company intends to invest in the construction of a high-precision printed circuit board project in Vietnam through a wholly-owned subsidiary, Singapore Shenghong, to produce high-layer printed circuit boards and HDI, with a planned investment of no more than US $260 million, including, but not limited to, new companies, land purchase, new plant and engineering construction, purchase of production equipment and supporting facilities, and other related matters. The company will implement the construction of Vietnam production base in stages according to market demand and business progress.
[other]
Citic Securities: Yang Minghui resigned as an executive director of the board of directors because of his retirement application.
Citic Securities (600030) announced on the evening of May 24th that Yang Minghui submitted his resignation report to the board of directors on May 24th, 2024. He applied to resign as an executive director of the eighth session of the board of directors, a member / chairman of a special committee under the board of directors, general manager, executive member, authorized representative and other positions held in the company and its holding subsidiary. During the vacancy of the general manager of the company, Zhang Youjun, executive director and chairman of the board, shall perform the duties of the general manager of the company.
China General Nuclear Corporation: Fangchenggang Unit 4 is about to have commercial operation conditions.
China General Nuclear Corporation (003816) announced on the evening of May 24th that the No. 4 unit of Guangxi Fangchenggang Nuclear Power Co., Ltd. (referred to as "Fangchenggang Nuclear Power Co., Ltd."), the company's holding subsidiary, is expected to complete all commissioning work on May 25, with commercial operation conditions. Fangchenggang Nuclear Power will also apply for power business license (Golden Kirin analyst) and other documents in accordance with the relevant requirements. Under normal circumstances, after the completion of the relevant procedures, the above time will be recognized as the time when the unit is put into commercial operation.
Yaben Chemistry: subsidiary Nantong Yaben resumes production ahead of schedule on June 1
Abbott Chemical (300261) announced on the evening of May 24th that the company's wholly-owned subsidiary Nantong Yaben Chemical Co., Ltd. (referred to as "Nantong Yaben") is scheduled to resume production ahead of schedule on June 1st, 2024. During this shutdown period, Nantong Yaben's other business activities except production are carried out normally, and the product inventory meets the sales demand during the temporary shutdown period. At the same time, due to multiple factors such as policy, market and technology, the schedule of the new project is not expected to contribute to the operating performance of Nantong Yaben during the year. In view of this, this temporary shutdown will not have a significant impact on the company's production and operation plan for 2024.
Wangfujing: Guiyang Xinyin 1950 Discovery Shopping Center is open to the public.
Wangfujing (600859) announced on the evening of May 24th that the Guiyang Xinyin 1950 Discovery Shopping Mall will be open to the public on May 25 under the company's flag (Jin Kirin analyst). As of the date of this announcement, the company has operated a total of 79 large integrated retail stores nationwide.
Shaanxi Energy: winning the Mining right of Qianyangshan Coal Mine in Huanxian County, Gansu Province
Shaanxi Energy (001286) announced on the evening of May 24th that the company successfully won the mining right of Qianyangshan Coal Mine in Huanxian County, Gansu Province with 37.35 million yuan, resource reserves: 1.0198398 billion tons of coal.
Emeishan A: signed a cooperation agreement with Leshan Electric Power on tourism development in Emeishan City.
Emeishan A (000888) announced on the evening of May 24th that the company recently signed a "Cooperation Agreement on coordinated Promotion of the High-quality Development of Tourism in Emeishan City" ("Development Cooperation Agreement") with Leshan Power supply Company and Leshan Electric Power Co., Ltd., the State Grid Sichuan Electric Power Company. It is intended to cooperate in promoting the deep integration of the tourism industry and the power industry. The signing of the Development Cooperation Agreement enables all parties to jointly explore opportunities for cooperation in the field of new energy, to jointly carry out the co-construction and sharing of tourism projects and power facilities, and the market development of tourism and power industries.
Luzhou laojiao: the controlling shareholder renews the agreement of unanimous action
Luzhou laojiao (000568) announced on the evening of May 24th that recently, the company received notice from the controlling shareholder Laojiao Group that Laojiao Group and Xingyi Group, the company's second largest shareholder, renewed the agreement on concerted action on May 23rd. Before and after the renewal of the unanimous action agreement, the ownership structure of the company has not changed and the control has not been transferred.
Green Precision: the subsidiary signed an intention agreement with VISP to lease the land use right
Green Precision (300968) announced on the evening of May 24th that in order to comply with the trend of international development, promote the strategic layout of overseas manufacturing bases, and better meet the needs of overseas customers such as product delivery, Vietnam Green recently signed an intention agreement with VSIP to lease land use rights. Vietnam Green leases land at VSIP BAC NINH II INDUSTRIAL PARK. (VSIP second Industrial Park, Peinin Province, Vietnam) for a total price of 207.576 billion dong (excluding tax) to VSIP until January 22, 2069.
Baolijia: subsidiary Yantai Baolijia implemented relocation and production suspension.
Baolijia (301037) announced on the evening of May 24th that Yantai Baolijia Chemical Technology Co., Ltd. (referred to as "Yantai Polijia"), a wholly owned subsidiary of the company, needs to transfer the production capacity of the Yantai Baolijia plant due to the adjustment of the company's business strategy. Yantai Baolijia production line has been suspended recently. The relocation and suspension of Yantai Baolijia factory does not have a significant impact on the company's daily production and operation and the company's sustainable operating capacity at the present stage, but it will result in corresponding relocation costs, disposal loss fees and so on.
China Resources Materials: sign a tripartite cooperation agreement on processing and production of PTA
Recently, the company and its subsidiaries China Resources Chemical International Trading (Shanghai) Co., Ltd., China Resources Chemical New Materials Co., Ltd., China Resources Chemical International Co., Ltd., and Hanbang (Jiangyin) Petrochemical Co., Ltd. (Jiangyin Hanbang) commissioned Jiangyin Hanbang to process and produce refined terephthalic acid (the company's main raw materials). Referred to as "PTA"), it is proposed to sign a tripartite cooperation agreement, the raw material for processing p-xylene is supplied by the company's wholly-owned subsidiary, and the PTA processing fee is based on the average processing price difference in the PTA market in that month and is given a certain discount, of which 10 yuan per ton for ton bag delivery and 40 yuan per ton for tanker delivery, processing costs are expected to be no more than 300 million yuan during the validity of the contract, and it is expected to reduce the company's PTA procurement costs to no more than 40 million yuan.
Sichuan Road and Bridge: the subsidiary intends to participate in the bidding for the new Miansui railway station project in front of the Miansui railway with the subscription fund model.
Sichuan Road and Bridge (600039) announced on the evening of May 24th that the subsidiaries of the company intend to form a consortium to participate in the bidding for the construction total price contract project in front of the Mianyang-Suining section of the Mianyang-Neijiang railway. After winning the bid for the project, the subsidiary of the company intends to subscribe for the share of the partnership (limited partnership) of the Sichuan Miansui Railway Equity Investment Fund (Phase I) designated by the tenderer Miansui Railway Co., Ltd., and the contribution amount of the fund shall be 5% of the winning bid amount of the project. According to the calculation of the two bidding sections with the highest bid limit at the same time, the company intends to subscribe for a maximum fund share of 1.962 billion yuan. The consortium shall be responsible for the construction, fund raising, fund payment, fund withdrawal and other matters of the project.
Dizhe Medicine: the latest research achievement of Shuvozhe ®was selected as the report of the American Society of Clinical Oncology (ASCO) meeting in 2024.
Dizhe Pharmaceutical (688192) announced on the evening of May 24th that the company will hold the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 to June 4, 2024. Two new studies on epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutant advanced non-small cell lung cancer (NSCLC) by Shuvozhe ®(common name: Shuvotinib), a new type of lung cancer targeting class I, were announced. Among them, the data of the globally registered clinical study "Wukong 1B" (WU-KONG1 PartB) of Shu Wozhe ®in the treatment of EGFR Exon20ins mutant NSCLC will be released for the first time in the form of an oral report. The results of preliminary analysis showed that the study had reached its predetermined end point, and the treatment of EGFR Exon20ins mutant NSCLC with the second / posterior line of ®showed positive anti-tumor efficacy and good safety.
ZG005 and ZGGS18 will release clinical data and latest progress at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2024.
Zeta Pharmaceutical (688266) announced on the evening of May 24th that the clinical research data and latest progress of the company's independently developed new drugs ZG005 and ZGGS18 will be released at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2024. The release of clinical data and the latest developments at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO) will not have a significant impact on the company's near-term performance.
Cylon Pharmaceutical: subsidiary obtains notice of approval of application for listing of lysine aspirin chemical raw materials
Sailong Pharmaceutical (002898) announced on the evening of May 24th that Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary, was recently approved and issued by the State Drug Administration of Lysine aspirin "Chemical API Application approval notice". The main indications of lysine aspirin are: for the treatment of fever and mild to moderate pain.
Zhenbao Island: obtain the registration certificate of Esmeprazole magnesium enteric-coated tablets
Zhenbao Island (603567) announced on the evening of May 24th that the company received the Drug Registration Certificate of esomeprazole magnesium enteric-coated tablets approved and issued by the State Drug Administration. Esomeprazole magnesium enteric-coated tablets are proton pump inhibitors and can effectively inhibit gastric acid secretion. Clinically, it is used for adult gastroesophageal reflux disease: treatment of reflux esophagitis, long-term treatment of cured esophagitis patients to prevent recurrence, symptom control of gastroesophageal reflux disease and so on.
Shanhe Drug Adjuvant: sodium stearate fumarate is jointly reviewed and approved by CDE and preparation.
Shanhe Pharmaceutical Additive (300452) announced on the evening of May 24th that recently, the "sodium stearate fumarate" medicinal excipients submitted by the company has been jointly reviewed and approved by the Drug Evaluation Center of the State Drug Administration (CDE) and the preparation. Sodium fumarate stearate is mainly used as a lubricant for tablets and capsules. It is compatible with most API and is an excellent substitute for magnesium stearate.
Dongcheng Pharmaceutical Co., Ltd.: holding subsidiary obtains approval notice of drug clinical trial
Dongcheng Pharmaceutical (002675) announced on the evening of May 24th, on May 23rd, Yantai Lanacheng Biotechnology Co., Ltd., a subsidiary of the company, received a notice of approval for the clinical trial of 177Lu-LNC1010 injection approved by the State Drug Administration, and agreed to carry out the clinical trial of gastroenteropancreatic neuroendocrine tumor.
Baiotai: BAT6005 combined with BAT1308 injection to obtain approval notice of drug clinical trial
Baiotai (688177) announced on the evening of May 24th that it recently received the "Drug Clinical trial approval notice" approved and issued by the State Drug Administration, and the company obtained approval for the clinical trial application of BAT6005 combined with BAT1308 injection in the treatment of locally advanced or metastatic solid tumor.
Fosun Pharmaceutical: holding subsidiary receives application for drug registration
Fosun Pharmaceutical (600196) announced on the evening of May 24th that the application for drug registration of Fumetinib tablets independently developed by the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. for the treatment of adult dendritic cell and histiocytic tumors was recently accepted by the State Drug Administration; previously, the indication has been included in the priority review process.
Shanghai Pharmaceutical: notice of approval of clinical trial for I040
Shanghai Pharmaceutical (601607) announced on the evening of May 24th that the application for "I040" clinical trial developed by the company received the "Drug Clinical trial approval notice" approved and issued by the State Drug Administration. I040 is a small molecular compound. Preclinical studies have shown that I040 can improve core symptoms in several animal models of depression, and it is safe.
Sinopec: notice of approval for clinical trials of GB08 injection
Sinopec (688136) announced on the evening of May 24th that Shenzhen Kexing, a wholly owned subsidiary, received the "Drug Clinical trial approval notice" issued by the State Drug Administration, which approved Shenzhen Kexing to carry out the clinical trial of "GB08 injection". GB08 injection is the first class I innovative drug independently developed by the company. It is a long-acting growth hormone based on Fc fusion protein independently developed by the company according to the needs of clinical patients and based on children's growth hormone deficiency.